N4 Pharma Share Discussion Threads

[earwacks] 01/11/2022 21:20

Sounds pretty sensible to me that if you are trialing a new possible treatment or aid to treatment that as it progresses and evolves with new possibilities it would be advisable to ‘enhance’; or expand’ the patent to cover new horizons. Not sure that I would count vague insinuation as 28 years of knowledge but hey ho

[barrie16] 01/11/2022 17:11

Nobby

I'm not saying don't post! I couldn't understand why you would want to be interested in a company you don't believe will succeed or a ceo you don't rate. it's great to have a interest in the technology though. How many pharma companies do you follow and post on? I do know nobby, what it's like to have an interest in a small company that fails, I held UTN for a long time.

[nobbygnome] 01/11/2022 16:42

That usual old chestnut. Well during my 28 year Pharma career I worked on a similar product for a while so have an interest in the technology. I would have thought you would be grateful to get the benefit of my knowledge but hey ho.

As for Nigel let’s just say like most Aim CEOs he is economical with the truth. I don’t dispute he has a difficult job to get a technology to market with limited resources but some of his RNSs have been classics if you understand what really goes on in these experiments!

Whatever, I will continue to post whether you like it or not!

[barrie16] 01/11/2022 14:36

Hi Nobby If you don't think N4Pharma is worth investing In and you clearly don't like Theobald why continue to post on N4Pharma?????

[ch1rp] 01/11/2022 12:45

I think N4P know a little bit more than you Nobbs. After all you have been shorting here for years.

[1hh] 01/11/2022 07:41

This is all building the foundations for a rocket take off. It’s ensuring a tight ship to the patent before releasing the news we’ve all been waiting for nuvec to commercial production and real life use.

[nobbygnome] 01/11/2022 07:28

Uh oh it looks like they’ve had a pushback on their patent application. More than a little worrying….

[earwacks] 31/10/2022 17:21

I’m on the edge of the edge

[blackpoplar] 31/10/2022 15:36

I'm on the edge of my seat...

[bayley100] 17/10/2022 15:50

It's got to be soon surely

[mortimer7] 17/10/2022 13:31

No rational reason for my opinion, other than a hunch ( and a hope) that one day this will just take off.

[ch1rp] 17/10/2022 13:25

Looking forward to next exciting update:)

[blackhorse23] 10/10/2022 09:27

Bought RENE (LSE) last week, excellent data which could worth over 80m

[earwacks] 07/10/2022 15:58

Presumably the commercial viability of Nuvec. Can’t quite remember How Nigel put it when we were hoping the vaccine trials would produce a partner but with global patents in the bag it’s fair to assume it’s uses could be far reaching on a global scale. Am just amazed there is no meaningful institutional backing yet. Probably because it’s 5 million valuation prohibits them from buying any meaningful purchase and lack of shares available in any decent size. There is of course still considerable risk with so much other research but this does look quite a unique approach to me blocking cancer sells from multiplying would be fantastic. Remember also this is not a one trick pony

[pwal] 07/10/2022 15:29

What's leaking?

[jakleeds] 07/10/2022 15:00

Wow, nice jump but still worth only £5million. Loads more to go here yet. Maybe we’ve been tipped somewhere as well …

[pwal] 04/10/2022 09:37

Commence commercial outreach discussions. Sounds positive.

[jakleeds] 04/10/2022 07:16

Looks very promising

4 October 2022

N4 Pharma Plc

("N4 Pharma" or the "Company")

Double siRNA Testing Update

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R) , a novel delivery system for cancer treatments and vaccines, is pleased to announce successful in vitro testing of Nuvec(R) loaded with two small interfering RNA (siRNA) probes.

On 14 September 2022, the Company announced a strategic update highlighting its intention to focus its further development work on multiple loaded siRNA on Nuvec(R) .

T he Company has now completed initial in vitro testing of Nuvec(R) loaded with two generic siRNA probes, GFP (Green Fluorescent protein) and EHMT-2 (Euchromatic Histone Lysine Methyltransferase 2 ) at the same time. The siRNA probes were loaded onto Nuvec(R) in equal amounts, at a concentration previously shown to be active. Testing demonstrated that both siRNA probes when loaded onto Nuvec(R) were able to significantly silence their respective targets.

Nigel Theobald, Chief Executive Officer of the Company, commented :

"Showing that Nuvec(R) loaded with two generic siRNA probes still achieves significant silencing of their respective genes is validation for us to now begin the further work that we announced on 14 September with EGFR and BCl-2 in a PC9 lung cancer model.

"Achieving the initial successful testing of Nuvec (R) with the generic GFP and EHMT-2 siRNA will also allow us to commence commercial outreach discussions which will only be further strengthened by the results from the new work we are undertaking ."

[jakleeds] 26/9/2022 12:02

News due ??

[prumedheal] 15/9/2022 08:46

A company involved in cancer research, has huge potential globally as its sadly killing many, so I picked up a few this week, we see the potential here for nuvec (R) product, could see these rise substantially next few weeks and months now.

[prumedheal] 15/9/2022 08:42

A quiet board, and no nut-jobs.

Gret

[ga_dti] 15/9/2022 08:35

Latest CEO interview discussing development plans for commercialising Nuvec -